Subscribe our newsletter
Please Subscribe our news letter and get update.
Close
Overview:
About ALS
Amyotrophic Lateral Sclerosis (ALS), commonly known as Lou Gehrig’s disease, is a devastating motor neuron disease characterized by the progressive degeneration of nerve cells in the spinal cord and brain. Named after the renowned baseball player who succumbed to the disease, ALS primarily affects voluntary control of arms and legs, leading to difficulties in movement and, ultimately, trouble breathing. Despite its debilitating effects, ALS spares mental functioning and the senses, distinguishing it from some other neurological disorders.
The disease manifests in two main types:
Sporadic cases, which constitute 90-95% of occurrences, arise randomly without any known cause or family history.
In contrast, familial ALS is inherited and affects a smaller portion of individuals.
The age range for ALS onset is typically between 40 and 70, although cases can occur at a younger age. Unfortunately, there is currently no cure for ALS.
Symptoms of ALS may begin with weakness in a limb, progressing to additional limbs over weeks or months. Initial signs can also manifest as slurred speech or difficulty swallowing. As the disease advances, individuals may experience muscle twitching, cramping, and loss of motor control, leading to challenges in daily activities like walking and holding objects. ALS can eventually cause paralysis and respiratory failure.
Diagnosing ALS is challenging due to its similarity to other conditions. Electromyography (EMG), nerve conduction studies, MRIs, blood and urine tests, and spinal taps are commonly employed for diagnosis. While there is no cure for ALS, treatments focus on managing symptoms and improving quality of life.
Medications like Riluzole and Edaravone may slow disease progression, and supportive therapies, including physical, occupational, and speech therapy, aim to enhance mobility and communication. Psychological and social support, along with nutritional interventions, play crucial roles in providing holistic care.
Despite ongoing research, the cause of ALS remains unknown in most cases. Established risk factors include genetics, age, and gender. Early diagnosis is crucial for managing symptoms and implementing appropriate care plans. As ALS significantly impacts both individuals and their families, comprehensive support from healthcare professionals, social workers, and psychologists is essential in addressing the multifaceted challenges posed by this devastating disease.
Figure 1 Healthy spinal cord motor neuron vs ALS affected spinal cord motor neuron
To acquire a thorough insight into the progressing landscape of Amyotrophic Lateral Sclerosis (ALS) research and development, it is imperative to explore the present state of scientific inquiry and the emergence of innovative treatment strategies. This understanding serves as a vital compass for making informed decisions in the ALS therapy domain, guaranteeing strategic choices and the adept integration of treatments within the dynamic healthcare landscape.
Market Landscape: Amyotrophic Lateral Sclerosis (ALS): Example Illustration: Distribution by Pipeline Candidates
In the context of Amyotrophic Lateral Sclerosis (ALS) research and market analysis, company profiling plays a crucial role. It entails a thorough examination of companies involved in the ALS sector, offering a detailed view of a company’s historical background, product portfolio, financial stability, competitive strategies, and recent achievements. This valuable information aids in evaluating the competitive landscape within the ALS market, pinpointing opportunities for collaboration and strategic partnerships that can drive progress and innovation in the field.
Figure 2 Company Portfolio
In this report, we will conduct a thorough patent analysis to comprehensively evaluate the intellectual property landscape within the Amyotrophic Lateral Sclerosis (ALS) domain. This analysis seeks to reveal noteworthy patents, influential inventors, and emerging technological trends specific to the ALS sector.
Figure 3 Geographic coverage of where patent applications have been filed
Figure 4 Application Trend in Top Countries
The clinical trial analysis section in a market research report offers a comprehensive evaluation of clinical trials related to Amyotrophic Lateral Sclerosis (ALS). This includes a detailed breakdown of trial categories, study structures, research methods, and participant characteristics. Its main goal is to assess the effectiveness, safety, and outcomes of pharmaceuticals and medical interventions in the context of ALS.
Amyotrophic Lateral Sclerosis (ALS): Clinical Trial Analysis
Figure 5 Distribution by Key Geographical Areas
Figure 6 Distribution of ALS Drug Clinical Trials by Status
Figure 7 Distribution of Clinical Trials by Phase of Development
In a market research report centered on Amyotrophic Lateral Sclerosis (ALS), the market forecast section provides a thorough outlook on upcoming market trends, growth opportunities, and key factors influencing supply and demand dynamics. This segment presents quantitative predictions and offers valuable insights into market size, revenue forecasts, and potential avenues for growth within the ALS field.
Figure 8: Market Forecast
In this market research report focused on Amyotrophic Lateral Sclerosis (ALS), the competitive landscape section will provide a brief summary of key market participants, their respective market shares, and offer concise profiles outlining their strengths, weaknesses, and strategic approaches within the ALS domain.
Figure 10: Circumventing the Competitive part of Market landscaping
In order to give the most precise estimations and forecasts, Wissen Research uses an extensive and iterative research approach that is focused on reducing deviation. The company blends top-down and bottom-up methodologies for market segmentation and quantitative estimation. In addition, data triangulation, which examines the market from three separate angles, is a recurrent topic present in all of our research studies. Important components of the approach used for all of our studies include the following:
Preliminary data mining
On a wide scale, unprocessed market data is collected. Continuous data filtering makes sure that only verified and authenticated sources are taken into account. Additionally, data is extracted from a wide range of reports in our repository and from a number of reputable premium databases. We gather information from raw material suppliers, distributors, and purchasers to help with this since understanding the entire value chain is crucial for a thorough understanding of the market.
Surveys, technical symposia, and trade magazines are used to gather information on technical concerns and trends. Technical information focusing on white space and freedom of movement is also obtained from an intellectual property standpoint. Additionally, information on the industry’s drivers, constraints, and pricing patterns is obtained. As a result, a variety of original data are included in the material that is then cross-validated and certified with published sources.
Statistical model
We use simulation models to generate our market projections and estimates. Every study receives a special model that is tailored to it. Data for market dynamics, the technology environment, application development, and pricing patterns are gathered and supplied into the model all at once for analysis. The relative relevance of these factors is investigated, and their impact on the forecast period is assessed, using correlation, regression, and time series analysis. The process of market forecasting combines technological analysis with economic strategies, practical business acumen, and subject expertise.
Econometric models are frequently used for short-term forecasting, but technology market models are typically employed for long-term forecasting. These are based on a confluence of the business environment, regulatory environment, economic projection, and technical landscape. In order to develop global estimates, it is preferable to estimate markets from the bottom up by integrating data from key regional markets. This is required to ensure accuracy and a complete comprehension of the subject. Among the variables taken into account for forecasting are:
Regulations and anticipated developments
We give these criteria weights and use weighted average analysis to assess their market influence in order to calculate the anticipated market growth rate.
Primary research | Secondary research |
· Manufacturers · Technology distributors and wholesalers · End-user surveys · Consumer surveys | · Company reports and publications · Government publications · Independent investigations · Economic and demographic data · Online searches · Research reviews · Reference customers |
Table of Contents
1.1 Overview of Amyotrophic Lateral Sclerosis (ALS)
1.2 Key Findings
1.3 Market Insights and Recommendations
2.1 Research Background
2.2 Scope and Methodology
2.3 Report Structure
3.1 Definition and Classification of ALS
3.2 Symptoms, Diagnosis, and Clinical Presentation
3.3 Pathophysiology and Genetic Basis
3.4 Epidemiology and Prevalence
3.5 Causes and Risk Factors
3.6 Treatment
4.1 Market Size and Growth Trends, 2023-2033 (USD Million)
4.2 Market Segmentation (By Type, Treatment, Geography, etc.), 2023-2033 (USD Million)
4.3 Competitive Analysis of Key Players
4.4 Market Drivers and Challenges
5.1 Overview of ALS Patents
5.2 Top Assignees
5.3 Geography Focus of Top Assignees
5.4 Legal Status
5.5 Geography
5.6 Assignee Segmentation
5.7 Network Analysis of Top Collaborating Entities in ALS Treatments Patent Applications
5.8 Technology Evolution
5.9 Key Patents
5.10 Patent Trends and Innovations
5.11 Key Players and Patent Portfolio Analysis
6.1 Electro diagnostic Tests (EMG, NCS)
6.2 Genetic Testing
6.3 Imaging (MRI, CT)
6.4 Lumbar Puncture
6.5 Other Diagnostic Modalities
7.1 Chapter Overview
7.2 Analysis by Trial Registration Year
7.3 Analysis by Phase of Development
7.4 Analysis by Number of Patients Enrolled
7.5 Analysis by Status of Trial
7.6 Analysis by Study Design
7.7 Analysis by Type of Product
7.8 Analysis by Geography
7.9 Analysis by Key Sponsors / Collaborators
8.1 Medications (Riluzole, Edaravone)
8.2 Supportive Care
8.3 Assistive Devices
8.4 Emerging Treatment Approaches
8.5 Product Analysis of Treatment Options
9.1 North America
9.1.1 Total Market Size of ALS in North America (2023-2033)
9.1.2 Market Size of ALS by Therapies in North America (2023-2033)
9.2 Europe
9.2.1 Total Market Size of ALS in Europe (2023-2033)
9.2.2 Market Size of ALS by Therapies in Europe (2023-2033)
9.3 Asia-Pacific
9.3.1 Total Market Size of ALS in Asia-Pacific (2023-2033)
9.3.2 Market Size of ALS by Therapies in Asia-Pacific (2023-2033)
9.4 Latin America
9.4.1 Total Market Size of ALS in Latin America (2023-2033)
9.4.2 Market Size of ALS by Therapies in Latin America (2023-2033)
9.5 Middle East and Africa
9.5.1 Total Market Size of ALS in Middle East and Africa (2023-2033)
9.5.2 Market Size of ALS by Therapies in Middle East and Africa (2023-2033)
10. Competitive Landscape
10.1 Company Profiles
10.2 Product Portfolio Analysis
10.3 Recent Developments and Strategies
11. Future Outlook and Market Opportunities
11.1 Advancements in Research and Technology
11.2 Unmet Needs and Potential Market Gaps
11.3 Market Forecast and Growth Opportunities
12. Conclusion
13. Appendix
a. Glossary of Terms
b. List of Abbreviations
c. References
S.no | Key Highlights of Report | |
1. | Patent Analysis | · Top Assignee · Geography focus of top Assignees · Assignee Segmentation · Network analysis of the top collaborating entities in Amyotrophic Lateral Sclerosis (ALS) therapy patent applications · Technology Evolution · Key Patents · Application and Issued Trend · Key technology |
2. | Market analysis | · Current Treatment Options · Emerging Therapies and Research Developments (by product analysis and scientific analysis) · Strategic activities · Therapeutic activity of drugs · Company portfolio · Detailed profiles of the key players that are engaged in the development of approved drugs · Strategic Activities |
3. | Clinical Trials | · Analysis of clinical trial through graphical representation · Coverage of treatments from pre-clinical phases till commercialization (also including terminated and completed studies) |
4. | Forecast | · Detailed comprehension of the historic, current and forecasted trend of market by analysis of impact of these treatments on the market |
5. | Opportunity Analysis | · Technology evolution based on problem solution · Potential licensees · Geography of suppliers · Treatment trends · Unmet needs · SWOT · Drivers and barriers |
6. | KOLs | · A detailed analysis and identification of the key opinion leaders (KOLs), shortlisted based on their contributions |
LIST OF FIGURES
Figure number | Description |
Figure 1 | Terminology of Amyotrophic Lateral Sclerosis (ALS) Over The Years |
Figure 2 | Amyotrophic Lateral Sclerosis (ALS) Treatment– History and Present |
Figure 3 | Projection of Amyotrophic Lateral Sclerosis (ALS) till 2033 in different geographies |
Figure 4 | Technology Categorization Of Drug Delivery Methods For Amyotrophic Lateral Sclerosis (ALS) |
Figure 5 | Recent Technology Trends in Amyotrophic Lateral Sclerosis (ALS) |
Figure 6 | Technology Evolution in Drug Delivery Market of Amyotrophic Lateral Sclerosis (ALS) |
Figure 7 | Geographical Distribution of Patents of Top Assignees |
Figure 8 | Assignee Segmentation (Companies) |
Figure 9 | Assignee Segmentation (Educational Establishment) |
Figure 10 | Patent Based Key Insights Of xx |
Figure 11 | Patent Based Key insights of xx |
Figure 12 | Patent Based Key insights of xx |
Figure 13 | Geographic Distribution of the Universities/Research Organizations Filling Patents On Various Drug Delivery Approaches |
Figure 14 | Key Summary Regarding the Patent Filing On Amyotrophic Lateral Sclerosis (ALS) |
Figure 15 | Product Pipeline of Different Approaches with Companies Name |
Figure 16 | Portfolio for Approved Product |
Figure 17 | Clinical Trials Conducted till Date by Different Companies and Universities |
Figure 18 | Clinical Trials based Key Insights |
Figure 19 | Key Growth Drivers for Amyotrophic Lateral Sclerosis (ALS) Market |
Figure 20 | Restraints for Amyotrophic Lateral Sclerosis (ALS) Market |
Figure 21 | xx Portfolio (Top Player) |
Figure 22 | xx Portfolio (Top Player) |
Figure 23 | xx Portfolio (Top Player) |
Figure 24 | xx Portfolio (Top Player) |
Figure 25 | xx Portfolio (Top Player) |
Figure 26 | xx Portfolio (Start-up) |
Figure 27 | xx Portfolio (Start-up) |
Figure 28 | xx Portfolio (Start-up) |
Figure 29 | Strategic Activities Including Collaboration, Partnerships and Acquisitions |
Figure 30 | Research Methodology for Patent, Selection and Analysis |
Figure 31 | Research Methodology for Clinical Trials, Selection and Analysis |
LIST OF GRAPHS
Graph number |
Description |
Graph 1 | Number of people worldwide with Amyotrophic Lateral Sclerosis (ALS) |
Graph 2 | Problem Solution Analysis |
Graph 3 | Top Assignees in Amyotrophic Lateral Sclerosis (ALS) |
Graph 4 | Technology Focus of Top Assignees (IPC-CPC Classes) |
Graph 5 | Top Countries of Origin of Patents |
Graph 6 | New entrants in drug delivery field |
Graph 7 | Legal Status |
Graph 8 | Most Cited Patents |
Graph 9 | Patents with Largest Invention Families |
Graph 10 | Most Claim-Heavy Patents |
Graph 11 | Filing Trends |
Graph 12 | Clinical Trial Filing Timeline |
Graph 13 | Recruitment Status of the Clinical Trials Related to the Different Drug Delivery Approaches |
Graph 14 | Clinical Trials Phases with Respect to Specific Drug Delivery Approach |
Graph 15 | Weighted Scores for Top 64 Players According to Benchmarking Criteria |
Graph 16 | Amyotrophic Lateral Sclerosis (ALS) (CAGR: 2023-2033) |
Graph 17 | Amyotrophic Lateral Sclerosis (ALS) Market Share: Distribution by Key Geographical Area, 2023-2033 |
LIST OF TABLES
Table number | Description |
Table 1 | Parameters included and excluded for conducting the analysis |
Table 2 | Technology Classes with Definitions |
Table 3 | Patent Litigation |
Table 4 | Highest Market Valued Patents |
Table 5 | SWOT Analysis of Top 3 Players |
Table 6 | Parameters and their score for Benchmarking |
Table 7 | Weighted scores for top 5 players according to benchmarking criteria |